The addition of cannabidiol (CBD) to treatment for refractory epilepsy is associated with significant changes in the serum levels of several antiepileptic drugs (AEDs), abnormalities in liver function tests, and sedation, according to results published in Epilepsia.
Unlike tetrahydrocannabinol, cannabidiol reportedly lacks psychoactive effects and may be a treatmentoption for severe, refractory epilepsy.
There is limited data on the interaction between CBD and AEDs; however, it appear to modulate several cytochrome P450 (CYP) enzymes. Animal studies have linked CBD with potentiation and reduction in various AEDs thought to be secondary to its effects on CYP.
In the current study, Tyler E. Gaston, MD, of the University of Alabama at Birmingham Epilepsy Center, and colleagues, sought to identify interactions between CBD and commonly used AEDs. Data were obtained from the University of Alabama at Birmingham CBD open-label compassionate-use study that sought to investigate the addition of CBD to treatment regimens